Table 2: Intragroup analysis of different outcome measures between baseline and week 12.

MeasureOlanzapine
Baseline
Olanzapine
Week 12
95% CIRisperidone
Baseline
Risperidone
Week 12
95% CI

SAPS63.61 ± 3.8654.96 ± 3.429.1870.00016.77, 10.5362.19 ± 4.1156.31 ± 3.026.3150.00014.02, 7.74
SANS46.26 ± 3.3742.74 ± 3.693.8580.00031.69, 5.3546.83 ± 3.7545.28 ± 3.061.7540.08−0.22, 3.32
CGI-S3.65 ± 1.163.10 ± 1.031.9420.05−0.02, 1.123.25 ± 0.123.17 ± 0.162.1910.030.01, 0.15
SAI3.49 ± 0.613.83 ± 0.11−3.0040.003−0.57, −0.113.51 ± 1.033.97 ± 0.74−1.9870.05−0.92, 0.00
SAS0.35 ± 0.760.38 ± 0.02−0.2160.82−0.31, 0.250.36 ± 0.110.45 ± 0.19−2.2450.02−0.17, −0.01

SAPS: Scale for Assessment of Positive Symptoms; SANS: Scale for Assessment of Negative Symptoms; CGI-S: Clinical Global Impressions-Severity Scale; SAI: Schedule for Assessment of Insight; and SAS: Simpson Angus Scale.